Drugs / SIM0916
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT07402512 | Mar 2026 → Mar 2027 expected | respiratory syncytial virus infectious disease | Simcere Pharmaceutical Co., Ltd | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SIM0916 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07402512 ↗ |
| Route | Oral | “for Oral Suspension” NCT07402512 ↗ |